CKD Bolsters Chronic, Orphan Portfolio In String Of Deals
This article was originally published in PharmAsia News
Executive Summary
South Korea's Chong Kun Dang is diversifying its drug portfolio by licensing in several products from foreign pharma firms in a move that seems to be aimed at minimizing profit declines stemming from investment in R&D and gaining new engines of future growth.